+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Life-Threatening Effects of Antipsychotic Drugs

  • ID: 3692676
  • Book
  • 394 Pages
  • Elsevier Science and Technology
1 of 4

Life-Threatening Effects of Antipsychotic Drugs describes in detail more than 20 life-threatening effects associated with antipsychotics, presents the best available data on their incidence and case fatality, and gives comprehensive advice on diagnosis, management and preventive strategies. In addition, the book discusses the benefit of antipsychotic medication in a range of therapeutic indications, and demonstrates the gain in life-expectancy associated with clozapine use in severe mental illness despite its serious, potentially life-threatening adverse effects.

  • Covers cardiovascular, neurological, muscular, hematological, gastrointestinal, autonomic and metabolic effects
  • Gives advice on risk factors, confounding diagnoses and measures to minimise seriousness
  • Discusses clozapine rechallenge after each of its serious adverse reactions
  • Makes suggestions for optimum management of somatic disease in those with severe mental illness, to improve life-expectancy
  • Includes data on post-mortem considerations

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 4

Part I: Cardiovascular Adverse Effects of Antipsychotic Drugs

Chapter 1
Sudden Cardiac Death and Ventricular Arrhythmias

Peter Manu, Anca Dan and Gheorghe-Andrei Dan

Chapter 2
Myocarditis and Cardiomyopathy

Kathlyn J. Ronaldson

Chapter 3
Pulmonary Embolism

Peter Manu, Christopher Hohman, James F. Barrecchia, and Matisyahu Shulman

Chapter 4
Orthostatic Hypotension

James J. Gugger and Megan J. Ehret

Part II: Hematological Complications of Treatment With Antipsychotic Drugs

Chapter 5
Severe Neutropenia and Agranulocytosis

John Lally and Robert J. Flanagan

Part III: Antipsychotic-Related Pathology of the Digestive System

Chapter 6
Gastrointestinal Hypomotility and Dysphagia

Robert J. Flanagan and Kathlyn J. Ronaldson

Chapter 7
Liver Failure

Katie F.M. Marwick

8. Pancreatitis

Peter Manu, Matisyahu Shulman and Kathlyn J. Ronaldson

Part IV: Major Neurological and Neuromuscular Adverse Effects of Antipsychotic Drugs

Chapter 9

Tilman Steinert and Walter Fröscher

Chapter 10
Neuroleptic Malignant Syndrome

Julie Langan Martin and Daniel J. Martin

Chapter 11
Heat Stroke and Rhabdomyolysis

Kathlyn J. Ronaldson

Part V: Metabolic Complications of Antipsychotic Drug Treatment

Chapter 12
Type 2 Diabetes Mellitus

Davy Vancampfort, Richard I.G. Holt, Brendon Stubbs, Marc De Hert, Katherine Samaras and Alex J. Mitchell

Part VI: Other Life-Threatening Effects of Antipsychotic Drugs

Chapter 13
Interstitial Nephritis and Interstitial Lung Disease

Kathlyn J. Ronaldson

Part VII: Clinical and Forensic Challenges in the Use of Antipsychotic Drugs

Chapter 14
The Benefits of Antipsychotic Drugs: Symptom Control and Improved Quality of Life

Jian-Ping Zhang

Chapter 15
Antipsychotic-Related Mortality: Risk and Strategy for Improved Clinical Management

Dan Cohen

Chapter 16
Forensic Investigation of Antipsychotic-Related Deaths

Robert J. Flanagan and Peter Manu

Note: Product cover images may vary from those shown
3 of 4


4 of 4
Manu, Peter
Peter Manu, MD is Professor of Medicine and Psychiatry at Hofstra University School of Medicine and Adjunct Professor of Clinical Medicine, Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine in New York. He aditionally serves as Director of Medical Services, Hillside Hospital, Long Island Jewish Medical Center. Prior to this, he served as the Medical Director, Alcohol and Drug Abuse Treatment Center at the University of Connecticut Health Center. In 2012 he received the Fulbright Specialist in Public/Global Health award from the U.S. Department of State. He is the author of 5 books, 68 journal articles, and 30 book chapters in psychiatry. He serves as an ad hoc reviewer for 38 journals in the areas of psychology, psychiatry, medicine, and pharmacology.
Flanagan, Robert J.
Professor Bob Flanagan is Consultant Clinical Scientist and Director, Toxicology Unit, King's College Hospital NHS Foundation Trust and Clinical Lead for Toxicology, Sheffield Teaching Hospital NHS Foundation Trust. He has published over 200 scientific papers and four books. Particular interests have been treatment of mental illness especially as regards use of antipsychotics, notably clozapine, treatment of cancer, especially in respect of the use of tyrosine kinase inhibitors such as imatinib, and the diagnosis of substance abuse, especially misuse of volatiles such as butane. He led on toxicology training for the Association for Clinical Biochemistry for many years, and regularly advises medical professionals, police, coroners, and prosecution and defence lawyers on toxicological issues. He has also acted as a consultant to the United Nations Office for Drugs and Crime, most recently as regards advising on methodology for the detection of drug-facilitated crime, and to the World Health Organization, notably in Serbia/Kosovo in 2007, and also in the Middle East and in India. He is immediate past-President of the British Academy of Forensic Sciences.
Ronaldson, Kathlyn J.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3692676